64CU-SAR-BISPSMA

64CU-SAR-BISPSMA

Rising Shares at Clarity Pharmaceuticals as it Launches Second Phase III Trial and Promotes Michelle Parker to CEO

Biotech Firm’s Ambitious Plans in Prostate Cancer Diagnosis In a significant move that is sending shockwaves through the biotech industry, Clarity Pharmaceuticals has announced the initiation of a second Phase III clinical trial for its revolutionary prostate cancer diagnostic product, 64CuSARbisPSMA..

64CU-SAR-BISPSMA

Positive guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III trial in patients with recurrence of prostate cancer

A Step Forward in Diagnosing Prostate Cancer The United States Food and Drug Administration (FDA) has provided positive guidance on a pivotal Phase III trial for 64CuSARbisPSMA, a novel diagnostic i..